share_log

新銳醫藥：截至二零二三年十二月三十一日止年度全年業績公告

NEW RAY MEDIC: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023

HKEX ·  Mar 25 22:02

Summary by Futu AI

新銳醫藥國際控股有限公司（「新銳醫藥」）公布截至2023年12月31日止年度全年業績，收益約50.2百萬港元，較2022年減少約44.1%。毛利約12.9百萬港元，較去年減少約2.3%。淨虧損約22.2百萬港元，較2022年減少約71.5%，並無派發末期股息。公司資產負債比率為零，並無銀行及其他借貸。新銳醫藥主要業務為醫藥產品分銷及貿易，及提供營銷及推廣服務，主要市場在中國。面對中國醫療行業改革政策及市場挑戰，公司積極調整業務策略，包括豐富產品組合、提高銷售及營銷能力，並專注於長期增長。公司於2023年度的收益下降，主要受到中國內地加強抗菌藥物分級分類管理政策的影響，導致主要產品需求下降。公司將繼續監控投資情況，並考慮出售非核心業務下的資產。
新銳醫藥國際控股有限公司（「新銳醫藥」）公布截至2023年12月31日止年度全年業績，收益約50.2百萬港元，較2022年減少約44.1%。毛利約12.9百萬港元，較去年減少約2.3%。淨虧損約22.2百萬港元，較2022年減少約71.5%，並無派發末期股息。公司資產負債比率為零，並無銀行及其他借貸。新銳醫藥主要業務為醫藥產品分銷及貿易，及提供營銷及推廣服務，主要市場在中國。面對中國醫療行業改革政策及市場挑戰，公司積極調整業務策略，包括豐富產品組合、提高銷售及營銷能力，並專注於長期增長。公司於2023年度的收益下降，主要受到中國內地加強抗菌藥物分級分類管理政策的影響，導致主要產品需求下降。公司將繼續監控投資情況，並考慮出售非核心業務下的資產。
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (“NEW PHARMACEUTICALS”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH REVENUES OF APPROXIMATELY HK$50.2 MILLION, DOWN APPROXIMATELY 44.1% COMPARED TO 2022. Gross profit was HK$12.9 million, down approximately 2.3% year-on-year. Net loss of approximately HK$22.2 million, down approximately 71.5% compared to 2022, and no final dividend was paid. The company has a zero balance of debt and no bank or other borrowing. The main business of Novi Pharmaceuticals is the distribution and trading of pharmaceutical products, as well as the provision of marketing and promotion services. Its main market is in China. In the face of China's healthcare reform policy and market challenges, the Company is actively adjusting its business strategy, including enriching its product...Show More
XINROI PHARMACEUTICALS INTERNATIONAL HOLDINGS LIMITED (“NEW PHARMACEUTICALS”) ANNOUNCED ITS ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023 WITH REVENUES OF APPROXIMATELY HK$50.2 MILLION, DOWN APPROXIMATELY 44.1% COMPARED TO 2022. Gross profit was HK$12.9 million, down approximately 2.3% year-on-year. Net loss of approximately HK$22.2 million, down approximately 71.5% compared to 2022, and no final dividend was paid. The company has a zero balance of debt and no bank or other borrowing. The main business of Novi Pharmaceuticals is the distribution and trading of pharmaceutical products, as well as the provision of marketing and promotion services. Its main market is in China. In the face of China's healthcare reform policy and market challenges, the Company is actively adjusting its business strategy, including enriching its product portfolio, increasing sales and marketing capabilities, and focusing on long-term growth. The Company's revenue declined in 2023, mainly due to the strengthening of the classification management policy of antibacterial drugs in the Mainland of China, which led to a decrease in demand for its main products. The company will continue to monitor the investment situation and consider selling assets under its non-core business.

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated